|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenograft was conducted to determine the effects of BCAR4 and <i>GLI2</i> on NSCLC tumorigenesis in vivo.
|
29615150 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the clinical diagnostic role of BCAR4 in tumors is not completely understood.
|
30537165 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo tumor xenograft study was used to verify the malignancy of CRC cells with inhibition of BCAR4.
|
30962766 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of lncRNA BCAR4 was related to lymph node metastasis (OR 3.68, 95% CI: 2.25-6.00; P < .001), high tumor stage (OR 3.19, 95% CI: 1.98-5.13; P < .001), and distant metastasis (OR 3.83, 95% CI: 2.15-6.82; P < .001), but not to tumor size.
|
31124974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis method did not alter the predictive value of BCAR4 on OS in various cancers.
|
31762809 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using RNA-Seq, RT-qPCR, bioinformatics, and studies utilizing the murine tumor xenograft model, we have found significant and consistent changes in the abundance of five lincRNAs (LINC00973, LINC00941, CASC19, CCAT1, and BCAR4) upon treatment of both HT-29 and HCT-116 cells with 5-fluorouracil, oxaliplatin, and irinotecan at different doses and durations; both in vitro and in vivo.
|
29870803 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, BCAR4 knockdown decreased tumor growth <i>in vivo</i>.
|
29190958 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor volume was monitored to evaluate the effect of BCAR4 on chondrosarcoma cell tumorigenicity.
|
28399646 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found that the expression of BCAR4 was significantly related to the size of the tumor, clinical classification and the survival time.
|
29028095 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of BCAR4 was significantly correlated with large tumor size, advanced Enneking stage, lung metastasis, and poor prognosis.
|
27460090 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of the present study identified a crucial tumor promotive role of BCAR4 in the progression of osteosarcoma, and suggested that BCAR4 may be a potential therapeutic agent for the treatment of osteosarcoma.
|
27874956 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven tumor cell growth, a clinical relevant observation.
|
26317614 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Regarding tumor aggressiveness high BCAR4 mRNA levels are associated with a shorter metastasis free survival and overall survival.
|
21506106 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting tumour aggressiveness.
|
20859285 |
2010 |